Pfizer Inc. PFE shares are trading lower by almost 1% on Monday as the company shared data from Phase 2b studies of berobenatide, an investigational GLP-1 receptor agonist for weight management. On ...

Pfizer aims to enter the weight loss drug market, and one platform should be the workhorse of this effort. That workhorse, called berobenatide, is performing as well as the company’s been hoping. It ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Pfizer hasn't yet tapped into the highly lucrative market of diabetes drugs that have been increasingly used for weight loss purposes. Searching for a weight-loss drug but don't like the idea of an ...

Add Yahoo as a preferred source to see more of our stories on Google. (NewsNation) — Some drugmakers are working on a potential breakthrough for people who take weight loss drugs: fewer injections.

NEW YORK, June 6 (Reuters) - Pfizer presented data on Saturday that showed a monthly dose of an experimental obesity drug it acquired through its purchase of ‌Metsera last year had a similar ...

(The Hill) – Pfizer announced Thursday plans to move forward with an oral daily weight loss medication in the same drug category as treatments including Ozempic and Zepbound. The pharmaceutical giant ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

GLP‑1 and next‑generation obesity drugs are gaining traction across the U.S. and globally, which is good news for investors.

While Novo Nordisk and Eli Lilly are now competing with each other with GLP-1 pills, Pfizer is still trying to get a GLP-1 drug out the door. But it has an ace up its sleeve. The company's ...